Compare · GLP-1 agonist
Mazdutide vs Retatrutide
Both are glp-1 agonist compounds. Here's how they line up on the evidence — graded the same way.
| Mazdutide | Retatrutide | |
|---|---|---|
| Evidence | Preliminary human | Preliminary human |
| Class | GLP-1 agonist | GLP-1 agonist |
| Summary | A GLP-1/glucagon dual agonist approved in China for weight loss and diabetes, with genuine RCT evidence that is still sponsor-funded and single-country. | An investigational triple-hormone agonist with striking weight-loss data in trials, but not yet FDA-approved and with no peer-reviewed Phase 3 results. |
| Full profile → | Full profile → |
Mazdutide
Mazdutide is an injectable drug for weight loss and type 2 diabetes that activates two metabolic hormone receptors at once. Unlike most of the attention-grabbing GLP-1 compounds, it is not stuck at the press-release stage: it has a published Phase 3 trial in a major journal and is actually approved…
Retatrutide
Retatrutide (Lilly code LY3437943) is an investigational injectable drug for obesity and type 2 diabetes. It has produced some of the largest weight-loss figures seen in trials so far, but as of June 2026 it is not approved anywhere and its pivotal Phase 3 data have not yet been peer-reviewed.